daratumumab (darzalex) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Daratumumab, sold under the brand name Darzalex, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$388.8300 - $2137.1200


$452.9225 - $1811.6900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( hyaluronidase (human recombinant) (hylenex), daratumumab (darzalex) - other name: daratumumab and hyaluronidase-fihj )
3003-005 | dararumumab | daratumumab | darzalex | humax-cd38 | jnj-54767414


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue